The data engineer started as a casual reader of the Jeffrey Epstein files. Then he became obsessed, and built the most ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion its initial public offering in the United States. The Somerville, ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has been ...

Brian Janous, a former Microsoft executive, and his firm Cloverleaf have become modern-day land men, packaging electricity and land for data centers.

UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial.

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Basil writes stories across the U.S. finance file including banks, asset managers, payment firms, insurers, and exchange operators. He also covers initial public offerings on U.S. exchanges and ...